Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Members of the Bcl-2 family of antiapoptotic proteins (Bcl-2, Bcl-XL and Mcl-1) are key regulators of apoptosis. The purpose of the present study was to examine and better define the role of Bcl-2, Bcl-XL and Mcl-1 in the progression of melanoma. Immunohistochemical staining for Bcl-2, Bcl-XL and Mcl-1 was performed on paraffin sections of 100 cases of benign nevi, primary melanoma and metastatic melanoma. Expression was correlated with histopathologic features, clinical progress and expression of transcription factors (AP-2, MITF and p-Stat3). Bcl-2 was expressed in 100% of benign nevi and thin melanoma (<or=1.0 mm) but was less in thick melanoma (>1.0 mm) (88%), subcutaneous (62%) and lymph node metastases (35%). In contrast, Bcl-XL and Mcl-1 were expressed at lower levels in nevi and thin melanoma compared to Bcl-2 but their expression was much higher in thick melanoma and in subcutaneous and lymph node metastases (P<0.0001). Bcl-2 expression was negatively associated with tumor thickness (P<0.05) but Bcl-XL expression increased with increasing tumor thickness (P<0.05) and dermal tumor mitotic rate (P<0.05). Similarly Mcl-1 expression increased with increasing tumor thickness (P<0.09) and dermal tumor mitotic rate (P<0.17). Bcl-2 expression was positively correlated with expression of the transcription factors microphthalmia transcription factor (MITF) and nuclear AP-2 whereas Bcl-XL (and Mcl-1) expression were positively correlated with p-Stat3. This study is the first to show a clear dissociation between changes in Bcl-2 expression (downregulation) and Bcl-XL, Mcl-1 expression (upregulation) during progression of melanoma. The results were also consistent with a role for AP-2 and MITF in regulation of Bcl-2 and pStat3 in regulation of Bcl-XL. These findings have important implications for the development of treatments targeting antiapoptotic proteins in patients with melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Constitutive STAT3 activation leads to evasion of apoptosis and a subsequent increase in cell survival.”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STAT3-mediated upregulation of Bcl-xL, Bcl-2, and Mcl-1 contributes to apoptosis evasion in several cancers.77–79”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STAT3 transcriptionally regulates several Bcl-2 family members, including the antiapoptotic proteins Bcl-xL, Bcl-2, and Mcl-1.77”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Expression of MITF, which correlates with increased lysosomal gene expression in melanoma cells100, decreases with disease progression97,101.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [97]
In the citing paper
“Furthermore, BH3-family proteins Bcl-XL and MCL-1, which disrupt the activation of autophagy by Beclin1, are upregulated in metastatic melanomas97.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · cited 1×
“Members of the Bcl-2 (B-cell lymphoma 2) family of proteins are key regulators of apoptosis”
BackgroundProapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., & Korsmeyer, S. J. (2001) · Science · doi:10.1126/science.1059108 · Cited by 3,988
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Boise, L. H., González-García, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., & Thompson, C. B. (1993) · Cell · doi:10.1016/0092-8674(93)90508-n · Cited by 3,087 · cited 1×
“The protein product of the longer Bcl-X mRNA (Bcl-XL) becomes as a repressor of apoptosis”
BackgroundChen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Involvement of the bcl -2 Gene in Human Follicular Lymphoma
Tsujimoto, Y., Cossman, J., Jaffe, E., & Croce, C. M. (1985) · Science · doi:10.1126/science.3874430 · Cited by 1,786
Cheng, E. H.-Y. A., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., & Korsmeyer, S. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00320-3 · Cited by 1,707 · cited 1×
“Bcl-2 associated X protein (Bax) and Bak are additional proapoptotic proteins that appear to be essential for induction of apoptosis”
BackgroundLetai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677 · cited 1×
“3 The precise interactions between the Bcl-2 proteins leading to apoptosis remain uncertain but two BH3 proteins, Bid and Bim, appear to directly activate Bax and Bak and bind to mitochondria”
BackgroundWillis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J. I., Adams, J. M., & Huang, D. C. S. (2005) · Genes & Development · doi:10.1101/gad.1304105 · Cited by 1,233 · cited 1×
“Recent studies have also suggested that there may be some selectivity of the proapoptotic BH3 only proteins for particular antiapoptotic proteins for example Noxa appears to bind to Mcl-1 and Bcl-XL but not Bcl-2”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961 · cited 1×
“7 Mcl-1 was first reported in differentiating myeloid cells”
BackgroundZhong, Q., Gao, W., Du, F., & Wang, X. (2005) · Cell · doi:10.1016/j.cell.2005.06.009 · Cited by 842 · cited 1×
“49 perhaps by the specific Mcl-1 ubiquitin ligase E3 (Mule)”
Background
Cited by
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
“Besides evading growth suppression signalling, by loss of TP53 function, tumours are also associated with an increase in the expression of anti-apoptotic regulators (Bcl-2, Bcl-xL and Mcl-1) and survival signals (Igf1/2) or downregulated pro-apoptotic factors (Bax, Bim and Puma) [96, 97].”
BackgroundSTAT3 as a target for inducing apoptosis in solid and hematological tumors
Al Zaid Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 487
Perciavalle, R. M., Stewart, D. P., Koss, B., Lynch, J., Milasta, S., Bathina, M., Temirov, J., Cleland, M. M., Pelletier, S., Schuetz, J. D., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2488 · Cited by 410
Mechanisms and prevention of UV‐induced melanoma
Sample, A., & He, Y. (2018) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/phpp.12329 · Cited by 372
Mcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Hu, Y., Dong, Z., & Liu, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02949-5 · Cited by 268
“Much evidence has shown that Bcl-2, BCL-XL, MCL-1 are highly expressed in tumors and correlate with histopathologic features, clinical progress and expression levels of phosphorylated STAT3 [103].”
BackgroundOncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., & Marais, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002734 · Cited by 278
“In agreement with this, low levels of MITF protein are found in invasive melanoma cells [14] and are associated with poor prognosis and disease progression in patients [15–17].”
ResultTargeting Mcl-1 for the therapy of cancer
Quinn, B. A., Dash, R., Azab, B., Sarkar, S., Das, S. K., Kumar, S., Oyesanya, R. A., Dasgupta, S., Dent, P., Grant, S., et al. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.609167 · Cited by 202
“However, studies done in paraffin sections of benign nevi, primary melanoma and metastatic melanoma showed an increase in Mcl-1 expression that correlated with melanoma progression [20,21].”
BackgroundWang, Y. F., Jiang, C. C., Kiejda, K. A., Gillespie, S., Zhang, X. D., & Hersey, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0665 · Cited by 194
Self-citationQuercetin exerts anti-melanoma activities and inhibits STAT3 signaling
Cao, H.-H., Tse, A. K.-W., Kwan, H.-Y., Yu, H., Cheng, C.-Y., Su, T., Fong, W.-F., & Yu, Z.-L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.008 · Cited by 187
Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
Rothberg, B. E. G., Bracken, M. B., & Rimm, D. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp038 · Cited by 180
Palmieri, G., Capone, M., Ascierto, M. L., Gentilcore, G., Stroncek, D. F., Casula, M., Sini, M. C., Palla, M., Mozzillo, N., & Ascierto, P. A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-86 · Cited by 177
Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management
Naik, P. P. (2021) · World Journal of Oncology · doi:10.14740/wjon1349 · Cited by 177
“Several genetic and immunohistochemical markers associated with the diagnosis of CM were summarized in Table 4 [54-79].”
BackgroundMicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma
Jin, L., Hu, W. L., Jiang, C. C., Wang, J. X., Han, C. C., Chu, P., Zhang, L. J., Thorne, R. F., Wilmott, J., Scolyer, R. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019312108 · Cited by 176
“Importantly, the Mcl-1 expression increases with melanoma progression in vivo (6), and is correlated with the expression ofGRP78, an indicator of activation of theUPR (7), and the expression of LDH5, an indicator of hypoglycemia that is one of the causes of ER stress (8).”
BackgroundSelf-citationInhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Shahar, N., & Larisch, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100712 · Cited by 165
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment
Correia, C., Lee, S.-H., Meng, X. W., Vincelette, N. D., Knorr, K. L. B., Ding, H., Nowakowski, G. S., Dai, H., & Kaufmann, S. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.03.012 · Cited by 166
Cutaneous Malignant Melanoma: Update on Diagnostic and Prognostic Biomarkers
Abbas, O., Miller, D. D., & Bhawan, J. (2014) · The American Journal of Dermatopathology · doi:10.1097/dad.0b013e31828a2ec5 · Cited by 162
Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles
Pan, J., Ruan, W., Qin, M., Long, Y., Wan, T., Yu, K., Zhai, Y., Wu, C., & Xu, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-19463-2 · Cited by 158
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2159 · Cited by 152
“Consistent with this notion are reports of modified expression of proapoptotic and antiapoptotic factors such as Bcl-2, Bcl-XL, and Mcl-1 in melanoma (3, 4).”
BackgroundJiang, C. C., Lucas, K., Avery-Kiejda, K. A., Wade, M., deBock, C. E., Thorne, R. F., Allen, J., Hersey, P., & Zhang, X. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0349 · Cited by 142
“We have previously shown that Mcl-1 expression is associated with melanoma progression, whereas Bcl-2 expression decreases during progression ofmelanoma ( 28 ).”
BackgroundSelf-citationAnti-tumor activity of splice-switching oligonucleotides
Bauman, J. A., Li, S., Yang, A., Huang, L., & Kole, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq731 · Cited by 141
“Metastatic melanoma is an aggressive malignancy with poor prognosis and disease progression is associated with increased Bcl-xL expression (25,26).”
BackgroundInhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide
Sinnberg, T. W., Lasithiotakis, K. G., Niessner, H., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Campos‐Domínguez, M., Gogel, J., Garbe, C., et al. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.379 · Cited by 144
“A recent immunohistochemical study demonstrated that Mcl-1 expression is associated with melanoma progression (Zhuang et al., 2007).”
BackgroundSolid Tumor Proteome and Phosphoproteome Analysis by High Resolution Mass Spectrometry
Zanivan, S., Gnad, F., Wickström, S. A., Geiger, T., Macek, B., Cox, J., Fässler, R., & Mann, M. (2008) · Journal of Proteome Research · doi:10.1021/pr800599n · Cited by 134
New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells
Gottfried, E., Lang, S. A., Renner, K., Bosserhoff, A., Gronwald, W., Rehli, M., Einhell, S., Gedig, I., Singer, K., Seilbeck, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066987 · Cited by 133
“The protein expression of other transcription factors, namely STAT3, a known critical regulator of melanoma development [34], and HIF-1a and HIF-2a, respectively, were not influenced by diclofenac (Fig.”
BackgroundAdaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma
Hersey, P., & Zhang, X. D. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00467.x · Cited by 123
“downregulated during progression of the disease and correlated with Stat-3 expression (Zhuang et al., 2007).”
Self-citationSeberg, H., Otterloo, E. V., & Cornell, R. A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12611 · Cited by 136
“Multiple studies have shown that TFAP2A expression is frequently decreased in melanoma cell lines and tumor samples relative to benign nevi (Baldi et al., 2001; Karjalainen, Kellokoski, Eskelinen, Alhava, & Kosma, 1998; Tellez et al., 2007; Woenckhaus et al., 2003; Zhuang et al., 2007).”
Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches
Eberle, J., Kurbanov, B. M., Hossini, A. M., Trefzer, U., & Fecker, L. F. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.09.001 · Cited by 122
Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
Lucas, K. M., Mohana‐Kumaran, N., Lau, D. T., Zhang, X. D., Hersey, P., Huang, D. C. S., Weninger, W., Haass, N. K., & Allen, J. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1166 · Cited by 112
“BCL-2 is only one of several related apoptosis proteins with altered expression in melanoma, for example, BCL-XL and MCL-1 are elevated during melanoma progression (9, 10) and these might prove superior targets for melanoma therapy.”
BackgroundSelf-citationMetabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 113
Huang, Q., Zhong, Y., Dong, H., Zheng, Q., Shi, S., Zhu, K., Qu, X., Hu, W., Zhang, X., & Wang, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111922 · Cited by 91
Self-citationHu, T., Zhang, C., Tang, Q., Su, Y., Li, B., Chen, L., Zhang, Z., Cai, T., & Zhu, Y. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-251 · Cited by 102
miR-339-3p Is a Tumor Suppressor in Melanoma
Weber, C. E. M., Luo, C., Hotz‐Wagenblatt, A., Gardyan, A., Kordaß, T., Holland‐Letz, T., Osen, W., & Eichmüller, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2932 · Cited by 98
“Especially MCL1 overexpression is suggested to contribute to chemotherapy resistance of melanoma after direct therapeutic targeting of BRAF and MEK (4, 5).”
BackgroundKong, L.-Y., Wei, J., Sharma, A. K., Barr, J., Abou-Ghazal, M. K., Fokt, I., Weinberg, J. S., Rao, G., Grimm, E. A., Priebe, W., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0618-y · Cited by 91
“In human melanoma patients, constitutive STAT3 was observed in the majority of tested melanoma cell lines and primary tumors, but not in normal skin specimens matched from the same patients [22] or from compound or dysplastic nevus tissues [37].”
Small molecules and targeted therapies in distant metastatic disease
Hersey, P., Bastholt, L., Chiarion‐Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I. C., Robert, C., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp254 · Cited by 95
Self-citationElgendy, M., Ciro, M., Abdel-Aziz, A. K., Belmonte, G., Zuffo, R. D., Mercurio, C., Miracco, C., Lanfrancone, L., Foiani, M., & Minucci, S. (2014) · Nature Communications · doi:10.1038/ncomms6637 · Cited by 83
Keuling, A. M., Felton, K. E. A., Parker, A., Akbari, M., Andrew, S. E., & Tron, V. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006651 · Cited by 80
“A number of studies have reported overexpression of Bcl-2, Mcl-1 and Bcl-xL in melanoma compared to normal tissue or benign nevi, although there is some controversy as to the role of Bcl-2 expression in chemoresistance [7,13,14,15].”
BackgroundYeh, C., Huang, W.-C., Rao, Y. K., Ye, M., Lee, W., Wang, L.-S., Tzeng, D. T. W., Wu, C., Shieh, Y., Huang, C. F., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt255 · Cited by 81
“Furthermore, recently results showed that the expression of Bax and that of Mcl-1 are independently regulated by ERK and STAT3 signaling pathways in NSCLC cells (40).”
BackgroundKhazen, R., Müller, S., Gaudenzio, N., Espinosa, E., Puissegur, M.-P., & Valitutti, S. (2016) · Nature Communications · doi:10.1038/ncomms10823 · Cited by 79
Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress
Dong, L., Jiang, C. C., Thorne, R. F., Croft, A. J., Yang, F., Liu, H., de Bock, C. E., Hersey, P., & Zhang, X. D. (2011) · Oncogene · doi:10.1038/onc.2011.87 · Cited by 80
“…family protein Mcl-1 is of particular importance in resistance of melanoma to treatment, in that its expression increases with melanoma progression and is associated with poorer prognosis (Cory and Adams, 2002; Mhaidat et al. , 2007; Wang et al. , 2007; Zhuang et al. , 2007; Jiang et al. , 2009a).”
Self-citationZhuang, L., Scolyer, R. A., Murali, R., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.129 · Cited by 83
“13 Previous immunohistological studies showed decreased levels of Bcl-2 with progression of melanoma”
BackgroundSelf-citationAnti-apoptotic proteins on guard of melanoma cell survival
Hartman, M. L., & Czyż, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.010 · Cited by 87
Chetoui, N., Sylla, K., Gagnon-Houde, J.-V., Alcaïde‐Loridan, C., Charron, D. J., Al‐Daccak, R., & Aoudjit, F. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0080 · Cited by 80
“higher than Bcl-2; the levels of which are mainly associated with melanocytes and benign nevi (38, 45-47).”
BackgroundRozovski, U., Wu, J. Y., Harris, D., Liu, Z., Li, P., Hazan‐Halevy, I., Ferrajoli, A., Burger, J. A., O'Brien, S. M., Jain, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534073 · Cited by 84
PAX3 Expression in Normal Skin Melanocytes and Melanocytic Lesions (Naevi and Melanomas)
Medic, S., & Ziman, M. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009977 · Cited by 82
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
Becker, T. M., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G. M., Scolyer, R. A., Mann, G. J., Kefford, R. F., Zhang, X. D., et al. (2013) · Oncogene · doi:10.1038/onc.2013.45 · Cited by 77
Self-citationMicroRNA-221 and -222 pathway controls melanoma progression
Felicetti, F., Errico, M. C., Segnalini, P., Mattia, G., & Carè, A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.11.1759 · Cited by 70
BCL2 Family, Mitochondrial Apoptosis, and Beyond
Dai, H., Meng, W., & Kaufmann, S. H. (2016) · Cancer translational medicine · doi:10.4103/2395-3977.177558 · Cited by 82
The three M’s: melanoma, microphthalmia‐associated transcription factor and microRNA
Bell, R. E., & Levy, C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00931.x · Cited by 68
Delyon, J., Chevret, S., Jouary, T., Dalac, S., Dalle, S., Guillot, B., Arnault, J., Avril, M., Bédane, C., Bens, G., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.07.839 · Cited by 70
“Activation of STAT3 has also been associated with melanoma progression (Kortylewski et al. 2005; Lee et al. 2012; Zhuang et al. 2007).”
BackgroundOncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition
Armstrong, J. L., Corazzari, M., Martin, S., Pagliarini, V., Falasca, L., Hill, D. S., Ellis, N., Al Sabah, S., Redfern, C. P. F., Fimia, G. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3003 · Cited by 65
Expression and Function of Bcl-2 Proteins in Melanoma
Eberle, J., & Hossini, A. M. (2008) · Current Genomics · doi:10.2174/138920208785699571 · Cited by 71
“Complicating an antisense strategy, Bcl-2 expression may also be reduced in metastatic melanoma [119], and other antiapoptotic Bcl-2 proteins such as Mcl-1 or Bcl-xL may substitute for Bcl-2 [120].”
BackgroundTargeting the intrinsic apoptosis pathway as a strategy for melanoma therapy
Mohana‐Kumaran, N., Hill, D. S., Allen, J. D., & Haass, N. K. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12242 · Cited by 65
“Other studies showed decreased BCL-2 expression during melanoma progression (Ramsay et al., 1995; Saenz-Santamaria et al., 1994; Tang et al., 1998; Tron et al., 1995; Zhuang et al., 2007).”
BackgroundGabellini, C., Gómez‐Abenza, E., Ibáñez‐Molero, S., Tupone, M. G., Pérez‐Oliva, A. B., de Oliveira, S., Bufalo, D. D., & Mulero, V. (2017) · International Journal of Cancer · doi:10.1002/ijc.31075 · Cited by 76
Zhang, Y. P., Li, Y., Lv, Y. T., & Wang, J. M. (2015) · Genetics and Molecular Research · doi:10.4238/2015.february.6.9 · Cited by 62
“A study by Zhuang et al. (2007) showed that p-STAT3 promotes the proliferation of melanoma cells by 1066 ©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 14 (1): 1056-1067 (2015)”
BackgroundYang, Z., Liu, Y., Liao, J., Cheng, G., Sun, C., Zhou, X., Wei, X., Zhang, T., Gao, Q., Ma, D., et al. (2015) · FEBS Journal · doi:10.1111/febs.13206 · Cited by 59
RetractedWroblewski, D., Mijatov, B., Mohana-Kumaran, N., Lai, F., Gallagher, S. J., Haass, N. K., Zhang, X. D., & Hersey, P. (2013) · Carcinogenesis · doi:10.1093/carcin/bgs330 · Cited by 57
Self-citationSeverin, F., Frezzato, F., Visentin, A., Martini, V., Trimarco, V., Carraro, S., Tibaldi, E. V., Brunati, A. M., Piazza, F., Semenzato, G., et al. (2019) · Cancers · doi:10.3390/cancers11121939 · Cited by 63
“The JAK2/STAT3 in particular has a key role in conveying signals that elicit the transcription of pro-survival and anti-apoptotic genes, such as Mcl-1 and Bcl-2, both known to be over-expressed in chronic lymphocytic leukemia (CLL) [6,7].”
BackgroundScolyer, R. A., Murali, R., McCarthy, S. W., & Thompson, J. F. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0612-rar.1 · Cited by 56
Self-citationRothberg, B. E. G., & Rimm, D. L. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.149 · Cited by 51
“…XIAP, and Bcl-2 family members Bax, Bak, Bok, Mcl-1, and PUMA (Tang et al., 1998; Baldi et al., 2004; Dai et al., 2004; Poyraz et al., 2004; Karst et al., 2005; Fecker et al., 2006; Niedojadlo et al., 2006; Zhuang et al., 2007; Bachmann et al., 2008; Emanuel et al., 2008; Wong et al., 2008).”
BackgroundMcl‐1 targeting could be an intriguing perspective to cure cancer
Blasio, A. D., Vento, R., & Fiore, R. D. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26786 · Cited by 59
“Although Mcl‐1 has sequence and functional similarity to Bcl‐2, nonetheless, in human tissues, its expression is regulated independently and has different tissue distributions (Krajewski et al., 1995; Zhang et al., 2010; Zhuang et al., 2007).”
BackgroundHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Gallagher, S. J., Tiffen, J. C., & Hersey, P. (2015) · Cancers · doi:10.3390/cancers7040870 · Cited by 51
“High levels of MAPK and/or PI3K signaling typical in melanoma increase levels of anti-apoptotic Bcl-2, Mcl-1, Bcl-XL, survivin and XIAP [65,74–79] while suppressing expression of the potent apoptotic inducer Bim and sequestering pro-apoptotic Bmf to the cytoskeleton [75,78,80–83].”
BackgroundSelf-citationSTAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma
Momtaz, S., Niaz, K., Maqbool, F., Abdollahi, M. R., Rastrelli, L., & Nabavi, S. M. (2016) · BioFactors · doi:10.1002/biof.1345 · Cited by 53
“The expression of Bcl-xL, Mcl-1, and antiapoptotic genes is downregulated through inhibition of Src or STAT3 [164].”
BackgroundInhibitors of Translation Initiation as Cancer Therapeutics
Lindqvist, L., & Pelletier, J. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.122 · Cited by 45
Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
Baranski, Z., de Jong, Y., Ilkova, T., Peterse, E. F. P., Cleton-Jansen, A., van de Water, B., Hogendoorn, P. C. W., Bovée, J. V. M. G., & Danen, E. H. J. (2015) · Oncotarget · doi:10.18632/oncotarget.5333 · Cited by 50
Towards new therapeutic approaches for malignant melanoma
Pacheco, I., Buzea, C., & Tron, V. A. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239941100202x · Cited by 54
(−)-Oleocanthal exerts anti-melanoma activities and inhibits STAT3 signaling pathway
Gu, Y., Wang, J., & Peng, L. (2016) · Oncology Reports · doi:10.3892/or.2016.5270 · Cited by 48
“In patient samples, the expressions of Bcl-xL and Mcl-1 were positively corrected with p-STAT3 expression (36).”
BackgroundRole of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets
Burroughs-Garcìa, J., Eufemiese, R. A., Storti, P., Sammarelli, G., Craviotto, L., Todaro, G., Toscani, D., Marchica, V., & Giuliani, N. (2021) · Cells · doi:10.3390/cells10061360 · Cited by 45
Mitochondrial apoptosis and BH3 mimetics
Dai, H., Meng, X. W., & Kaufmann, S. H. (2016) · F1000Research · doi:10.12688/f1000research.9629.1 · Cited by 48
Insights into melanoma: targeting the mTOR pathway for therapeutics
Pópulo, H., Soares, P., & Lopes, J. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.691472 · Cited by 50
“Bcl-2 expression does not correlate with prognosis in primary melanomas but its reduced expression levels were reported in metastases; in addition, both Bcl-xL and Mcl-1 were upregulated and correlated with melanoma progression [88,89].”
BackgroundEberle, J., Fecker, L. F., Hossini, A. M., Kurbanov, B. M., & Fechner, H. (2007) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00655.x · Cited by 46
Liu, Y. L., Lai, F., Wilmott, J. S., Yan, X. G., Liu, X. Y., Luan, Q., Guo, S. T., Jiang, C. C., Tseng, H.-Y., Scolyer, R. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2616 · Cited by 40
“Since Mcl-1 that can bind to and inhibit Noxa is also increased with melanoma progression [10, 24], and the ability of Noxa to trigger apoptosis is determined by a balance between its expression levels and the levels of Mcl-1 [37], it seems that high expression of Mcl-1 is sufficient to enable melanoma cells to withst…”
BackgroundInfluentialSelf-citationDriving transcriptional regulators in melanoma metastasis
Mobley, A. K., Braeuer, R. R., Kamiya, T., Shoshan, E., & Bar‐Eli, M. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9358-8 · Cited by 47
Treatment combinations targeting apoptosis to improve immunotherapy of melanoma
Hersey, P., & Zhang, X. D. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0732-5 · Cited by 44
Self-citationRosa, N., Speelman-Rooms, F., Parys, J. B., & Bultynck, G. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188791 · Cited by 51
Hakkim, F. L., Bakshi, H. A., Khan, S. S., Nasef, M., Farzand, R., Sam, S., Rashan, L. J., Al-Baloshi, M. S., Hasson, S. S., Jabri, A. A. A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26930 · Cited by 42
“The expression of MCL-1 is also known to increase in melanoma with disease progression [51].”
BackgroundPhyllodes Tumor of the Breast: Role of CD10 in Predicting Metastasis
Al-Masri, M. M., Darwazeh, G. A., Sawalhi, S., Mughrabi, A., Sughayer, M. A., & Al-Shatti, M. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2076-6 · Cited by 39
“3) expression.7 Immunoreactive score (IRS) was calculated by multiplying the percentage of positively staining cells by the intensity of staining as described by Zhuang et al.15”
MethodExpression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma
Westekemper, H., Karimi, S., Süßkind, D., Anastassiou, G., Freistuehler, M., Steuhl, K., Bornfeld, N., Schmid, K. W., & Grabellus, F. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.183939 · Cited by 38
“Zhuang et al found a significant correlation between Bcl-2 expression and tumour thickness in cutaneous melanoma with a higher expression in thinner tumours (<1 mm).(29) Conjunctival melanomas originating from PAM with atypia often tend to be flat rather than nodular.”
BackgroundInhibition of STAT 3 signalling contributes to the antimelanoma action of atractylenolide II
Fu, X., Chou, G., Kwan, H. Y., Tse, A. K., Zhao, L., Yuen, T., Cao, H., Yu, H., Chao, X., Su, T., et al. (2014) · Experimental Dermatology · doi:10.1111/exd.12527 · Cited by 37
Li, Y., & Orange, J. S. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001328 · Cited by 37
“In particular, a variety of escape mechanisms have been identified in cancer cells that mediate their resistance to NK cell or CTL attack [50,51].”
BackgroundCaarls, M. B., Wang, X., Arndt‐Jovin, D. J., Becker, D., & Jovin, T. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.296 · Cited by 36
Wroblewski, D., Jiang, C. C., Croft, A. J., Farrelly, M. L., Zhang, X. D., & Hersey, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084073 · Cited by 35
“levels decrease during progression of melanoma [41].”
Self-citationLai, F., Jiang, C. C., Farrelly, M. L., Zhang, X. D., & Hersey, P. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328353eff2 · Cited by 34
Self-citationBcl-xL: A Focus on Melanoma Pathobiology
Lucianò, A. M., Pérez‐Oliva, A. B., Mulero, V., & Bufalo, D. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052777 · Cited by 36
“A positive correlation between BCL2L1 expression and phosphorylated STAT3 was also identified in melanoma models [68].”
BackgroundZhao, Y., Zhang, Y., Yang, Z., Li, A., & Dong, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.148 · Cited by 33
“BCL2L1 and BIRC5 are highly expressed in melanoma cells, and increased expression correlates with tumor progression (Piras et al., 2007; Zhuang et al., 2007).”
BackgroundJazirehi, A. R., Baritaki, S., Koya, R. C., Bonavida, B., & Economou, J. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1296 · Cited by 32
“concordant with the protective role of Bcl-2 members in melanoma (40-44).”
RetractedLi, T., Fu, X., Tse, A. K., Guo, H., Lee, K. W., Liu, B., Su, T., Wang, X., & Yu, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-03351-2 · Cited by 30
Trisciuoglio, D., & Bufalo, D. D. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.027 · Cited by 35
Apoptosis Induced by Ginkgo biloba (EGb761) in Melanoma Cells Is Mcl-1-Dependent
Wang, Y., Lv, J., Cheng, Y., Du, J., Chen, D., Li, C., & Zhang, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124812 · Cited by 33
“The expression of Mcl-1 is also known to increase in melanoma with disease progression [50].”
BackgroundTseng, H., Jiang, C. C., Croft, A. J., Tay, K. H., Thorne, R. F., Yang, F., Liu, H., Hersey, P., & Zhang, X. D. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0646 · Cited by 31
Self-citationPark, J., Cho, S. Y., Kang, J., Park, W. Y., Lee, S., Jung, Y., Kang, M.-W., Kwak, H. J., & Um, J. (2020) · Biomolecules · doi:10.3390/biom10081098 · Cited by 29
“Investigation on melanoma samples revealed constitutive STAT3 activation is associated with anti-apoptotic factors such as Bcl-xL upon consistent progression [52].”
BackgroundKoschny, R., Brost, S., Hinz, U., Sykora, J., Batke, E. M., Singer, S., Breuhahn, K., Stremmel, W., Walczak, H., Schemmer, P., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-532 · Cited by 29
“[36] and applied to tumor tissue arrays [22].”
Brost, S., Koschny, R., Sykora, J., Stremmel, W., Lasitschka, F., Walczak, H., & Ganten, T. M. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.09.005 · Cited by 32
Schulte, J. H., Kirfel, J., Lim, S., Schramm, A. R., Friedrichs, N., Deubzer, H. E., Witt, O., Eggert, A., & Buettner, R. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.05.039 · Cited by 29
Novel inhibitors in the treatment of metastatic melanoma
Kalinsky, K. M., & Haluska, F. G. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.5.715 · Cited by 28
Keuling, A. M., Andrew, S. E., & Tron, V. A. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00698.x · Cited by 32
“Anti-apoptotic family members Mcl-1, Bcl-xl and Bcl-2 have been reported to be overexpressed in melanoma (Bush and Li, 2003; Leiter et al., 2000; Tang et al., 1998; Wong et al., 2008; Zhuang et al., 2007).”
BackgroundWu, Z., Cheng, X.-W., Wang, X.-N., & Ning-Jing, S. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834acc37 · Cited by 27
Rohrbeck, L., Gong, J., Lee, E. F., Kueh, A. J., Behren, A., Tai, L., Lessène, G., Huang, D. C. S., Fairlie, W. D., Strasser, A., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.96 · Cited by 29
“Although some report that BCL-2 is important for cell survival during the progression to malignant melanoma,(25) others reported that its expression is decreased in advanced melanomas compared with benign nevi.(26) In accordance with the latter reports, we found that treatment with the BCL-2-specific inhibitor, ABT-19…”
ResultmiR-596 Modulates Melanoma Growth by Regulating Cell Survival and Death
Liu, S., Lin, C.-H., Lu, J., Lin, I.-Y., Tsai, M.-S., Chen, M., & Ma, N. J.-L. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.11.016 · Cited by 28
“In particular, the anti-apoptotic proteins MCL1 and BCL2L1 are present at higher levels in many tumor types, including in 80% of melanomas (Ding et al., 2006; Wong et al., 2008; Zhuang et al., 2007).”
BackgroundSimultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells
Li, J., Xu, M., Yang, Z., Li, A., & Dong, J. (2010) · Cancer Investigation · doi:10.1080/07357900903286966 · Cited by 26
“BCL2L1 and BIRC5 are highly expressed in melanoma cells, and increased expression correlates with tumor progression (26, 27).”
BackgroundCellular demolition: Proteins as molecular players of programmed cell death
Dhuriya, Y. K., Sharma, D., & Naik, A. A. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.07.113 · Cited by 26
Metadata
- Authors
- Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P.
- Affiliations
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Corresponding author
- Hersey, Peter
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 20
- Issue
- 4
- Pages
- 416-426
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2086851270
- Cited by
- 202
- References
- 58
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 13 · 2016: 17 · 2015: 10 · 2014: 11 · 2013: 17 · 2012: 8
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 5764 d)
- Locations
- Modern Pathology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Medical Research Council
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma progression, Bcl-2, Bcl-xL, Mcl-1, anti-apoptotic proteins, apoptosis, STAT3 phosphorylation, MITF, AP2 transcription factor, tumor thickness, metastasis, benign nevi
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Lymph Nodes, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Neoplasm Proteins, Skin Neoplasms, Biomarkers, Tumor, Disease Progression, Fluorescent Antibody Technique, Indirect, Proto-Oncogene Proteins c-bcl-2, Transcription Factor AP-2, STAT3 Transcription Factor, bcl-X Protein, Microphthalmia-Associated Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.